The HOPO Project: Next-Generation Chelation

While Ca-DTPA and Zn-DTPA remain commonly used options for gadolinium chelation therapy, a next-generation chelator called HOPO (3,4,3-LI(1,2-HOPO), also known as HOPO-101) is under active development by HOPO Therapeutics. HOPO-101 is designed to be a potentially more effective and better-tolerated chelating agent for toxic heavy metals, including gadolinium. It was originally developed at Lawrence Berkeley National Laboratory and has demonstrated higher binding affinity for gadolinium compared to DTPA in preclinical studies.

One of the key advantages of HOPO-101 is that it is being developed as an oral medication, which could reduce the need for IV infusions and make chelation therapy more accessible to some patients if approved. Additionally, HOPO-101 appears to cause less mineral depletion than DTPA, which could reduce one of the most significant side effects of current chelation therapy. The drug is currently in clinical trials and is not yet available for general use.

For patients currently undergoing DTPA chelation, HOPO-101 represents a promising future option that may offer improved efficacy, convenience, and tolerability.

Potential Advantages Being Studied

•Oral administration: Being developed as a pill, which could reduce the need for IV infusions and make chelation more accessible — if it is approved
•Higher binding affinity: Demonstrated stronger binding to gadolinium compared to DTPA in preclinical studies
•Less mineral depletion: Appears to cause less loss of essential minerals like zinc and manganese
•Potential tolerability: Designed for improved patient comfort and fewer side effects, pending clinical trial results

Visit HOPO Therapeutics